Nanomaterial-enabled RNA therapeutics: bridging delivery barriers to clinical translation
- 1Department of Bioscience, Indrashil University
Abstract
RNA-based therapeutics have emerged as promising strategies for treating infectious diseases, cancer, and genetic disorders owing to their ability to regulate gene expression with high specificity. However, their clinical translation remains limited by poor physiological stability, rapid nuclease degradation, inefficient cellular uptake, endosomal entrapment, and unintended immune activation. Nanomaterial-based delivery systems have therefore become essential for protecting RNA cargo, improving intracellular transport, and enabling controlled cytosolic release. This review critically examines recent advances in nanomaterial-enabled RNA delivery platforms, including lipid nanoparticles, polymeric carriers, inorganic nanomaterials, and hybrid biomimetic systems, with emphasis on how nanocarrier physicochemical properties influence RNA loading, biodistribution, cellular internalisation, and endosomal escape. Unlike conventional reviews that separately discuss RNA modalities or delivery systems, this review integrates nanocarrier design, biological barriers, intracellular trafficking, and translational feasibility within a unified design-to-clinic framework, while comparatively analysing why lipid nanoparticles have achieved clinical success whereas many alternative platforms remain translationally limited. Major biological barriers and engineering strategies, including surface functionalization, ligand-mediated targeting, and stimuli-responsive architectures, are systematically correlated with therapeutic outcomes. The review further highlights key translational design principles underlying clinically successful RNA nanotherapeutics, including balancing systemic stability, efficient endosomal escape, biocompatibility, targeted biodistribution, and scalable manufacturing. Representative clinically approved and late-stage systems are discussed alongside current translational limitations, safety concerns, and regulatory challenges. Finally, emerging directions involving artificial intelligence-guided nanocarrier engineering, biomimetic delivery systems, and multifunctional co-delivery platforms are outlined to support the future development of clinically viable RNA therapeutics.
Related
- AI-integrated nanomaterial-based biosensors for biomedical diagnostics: engineering design, signal processing, and clinical translation.
- PDGFRα-directed fibroblast-homing peptides for targeted delivery of nucleic acid therapeutics
- Emerging perspectives in proteostasis: bridging mechanisms and therapeutics for human diseases
- Targeted protein degradation: bridging chemical biology and clinical translation
- AMPK-Directed Therapeutics for MASLD: Mechanistic Rationale, Activator Classes, and Clinical Translation
BibTeX
@article{pandey2026nanomaterialenabled,
title = {{Nanomaterial-enabled RNA therapeutics: bridging delivery barriers to clinical translation}},
author = {Kshipra Pandey and Sneha Jha and Loka Bikash Chaliha and Haren B. Gosai and Ritu Patel},
journal = {Frontiers in Nanotechnology},
year = {2026},
month = jun,
doi = {10.3389/fnano.2026.1860221},
url = {https://doi.org/10.3389/fnano.2026.1860221},
note = {CC BY},
}
RIS
TY - JOUR
TI - Nanomaterial-enabled RNA therapeutics: bridging delivery barriers to clinical translation
AU - Kshipra Pandey
AU - Sneha Jha
AU - Loka Bikash Chaliha
AU - Haren B. Gosai
AU - Ritu Patel
PY - 2026
DA - 2026/06/02
JO - Frontiers in Nanotechnology
DO - 10.3389/fnano.2026.1860221
UR - https://doi.org/10.3389/fnano.2026.1860221
AB - RNA-based therapeutics have emerged as promising strategies for treating infectious diseases, cancer, and genetic disorders owing to their ability to regulate gene expression with high specificity. However, their clinical translation remains limited by poor physiological stability, rapid nuclease degradation, inefficient cellular uptake, endosomal entrapment, and unintended immune activation. Nanomaterial-based delivery systems have therefore become essential for protecting RNA cargo, improving intracellular transport, and enabling controlled cytosolic release. This review critically examines recent advances in nanomaterial-enabled RNA delivery platforms, including lipid nanoparticles, polymeric carriers, inorganic nanomaterials, and hybrid biomimetic systems, with emphasis on how nanocarrier physicochemical properties influence RNA loading, biodistribution, cellular internalisation, and endosomal escape. Unlike conventional reviews that separately discuss RNA modalities or delivery systems, this review integrates nanocarrier design, biological barriers, intracellular trafficking, and translational feasibility within a unified design-to-clinic framework, while comparatively analysing why lipid nanoparticles have achieved clinical success whereas many alternative platforms remain translationally limited. Major biological barriers and engineering strategies, including surface functionalization, ligand-mediated targeting, and stimuli-responsive architectures, are systematically correlated with therapeutic outcomes. The review further highlights key translational design principles underlying clinically successful RNA nanotherapeutics, including balancing systemic stability, efficient endosomal escape, biocompatibility, targeted biodistribution, and scalable manufacturing. Representative clinically approved and late-stage systems are discussed alongside current translational limitations, safety concerns, and regulatory challenges. Finally, emerging directions involving artificial intelligence-guided nanocarrier engineering, biomimetic delivery systems, and multifunctional co-delivery platforms are outlined to support the future development of clinically viable RNA therapeutics.
SN - 2673-3013
ER -